Psychedelic Finance

Welcome to Psychedelic Finance. We exist to help bridge the gap between the exciting world of psychedelic medicine and the companies being built around it. If you'd like to see our more detailed research on the industry, you can join the community here: psychedelicfinance.com

Breaking: $CMPS reports Q1 2026 results with cash and cash equivalents of ~$216M, providing runway into 2027 as it advances late-stage COMP360 psilocybin trials toward potential commercialization for treatment-resistant depression.

Psychedelic medicines are getting a big boost of support from the White House. And it might be just the beginning of reshaping the future of psychedelic drugs in America. thenew.money/article/theres…

Psychedelic medicines are getting a big boost of support from the White House. And it might be just the beginning of reshaping the future of psychedelic drugs in America. $ATAI $CMPS $HELP $ENVB $CMND $DFTX thenew.money/article/theres…

Breaking: $ATAI says BPL-003 shows rapid and durable antidepressant effects in treatment-resistant depression, supporting Phase 3 trials set to begin in Q2 2026.

Deepfakes are a massive problem that could undermine the integrity of our health care systems and beyond. Glad to see more focus on addressing the need for authentication in the future of media, communication, and security.

Breaking: Compass Pathways has successfully achieved the primary endpoint for their COMP360 drug in their second Phase III trial for treating individuals with treatment resistant depression. $CMPS $ATAI

Breaking: $CMPS reports its COMP360 psilocybin treatment met the primary endpoint in its second Phase 3 trial for treatment-resistant depression.

Our next newsletter goes out soon. Discover the week's biggest news, top performing companies, and the Trends that moved markets. Join free: thenew.money/join

Billionaire @C_Angermayer is one of the world’s most prolific entrepreneurs and investors in technology and biotech. And his psychedelic drug development company is on a mission to change the future of psychedelic medicines in America. $ATAI thenew.money/article/christ…

This Week's Top Performing Trends +13.6% | Data Centre Stocks +11.8% | Mike Alfred +11.7% | Critical Minerals +11.7% | Future of Food +11.7% | Solar Power Stocks

Breaking: $CMPS gets FDA acceptance of its IND application for COMP360 in PTSD, enabling initiation of a late-stage clinical trial and hosting a webinar on PTSD and treatment-resistant depression.

Breaking: $CYBN rebrands to Helus Pharma - $HELP - and beings trading on Nasdaq.

@TheTape_TNM $ATAI $CYBN $MNMD next month?

December's top performing stocks on The New Money: $AMCI +1,231% $SIDU +462% $VELO +188% $OPTX +122% $HYMC +113% $PINK.V +94.7% $DRSHF +90.9% $LUNR +75.3% $TE +73.5% $PL +70.0% $RKLB +69.9% $GLO +67.9% $BRC +67.1% $RDW +62.1%

Top Performing Trends and Investors of 2025: Robert Friedland +1,076% Silver Stocks +320% Eric Sprott +288% America Backed +157% Rare Earth Elements +141% Gold Stocks +123% Critical Minerals +113% Mike Alfred +109% Eric Jackson +105% Stanley Druckenmiller +96% Drone Stocks +92%

@TheTape_TNM Is 2026 the year of psychedelic stock resurgence?

2025's Top Performing Stocks on The New Money: $SREMF +4,947% $KCP +1,800% $HG +1,310% $DSV +1,080% $HYMC +975% $MLP +950% $DFDV +628% $UCU +626% $TLO +567% $DVS +549% $GLAI +531% $ALM +526% $TMC +451% $FMS +450% $USAS +438% $DOMH +405% $PL +388% $APGO +383% $RAIN +382%

Discover the market's most notable options buys in real time on @TheNewMoney_app.

Breaking: $ATAI wins U.S. patent for its oral R-MDMA drug (EMP-01) to treat social anxiety disorder.

Discover today's top performing stocks on The New Money.